DRD2 and schizophrenia: Indeed, there is cumulative evidence that their antagonism of the dopamine D2 receptor, which is essentially the main target in the acute phase and relapse prevention of schizophrenia, and the anticholinergic action of APs may induce cognitive impairment in the long-term (Ballesteros et al., 2018; Feber et al., 2023; Hulkko et al., 2017; Husa et al., 2017).